296 related articles for article (PubMed ID: 19074080)
1. Gene replacement therapy for sickle cell disease and other blood disorders.
Townes TM
Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
[TBL] [Abstract][Full Text] [Related]
2. Correction of sickle cell disease by homologous recombination in embryonic stem cells.
Wu LC; Sun CW; Ryan TM; Pawlik KM; Ren J; Townes TM
Blood; 2006 Aug; 108(4):1183-8. PubMed ID: 16638928
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
[TBL] [Abstract][Full Text] [Related]
4. Correction of sickle cell disease in transgenic mouse models by gene therapy.
Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
[TBL] [Abstract][Full Text] [Related]
5. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.
Levasseur DN; Ryan TM; Pawlik KM; Townes TM
Blood; 2003 Dec; 102(13):4312-9. PubMed ID: 12933581
[TBL] [Abstract][Full Text] [Related]
6. Genetic strategies for the treatment of sickle cell anaemia.
Mansilla-Soto J; Rivière I; Sadelain M
Br J Haematol; 2011 Sep; 154(6):715-27. PubMed ID: 21707580
[TBL] [Abstract][Full Text] [Related]
7. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
[TBL] [Abstract][Full Text] [Related]
8. Correction of the sickle cell mutation in embryonic stem cells.
Chang JC; Ye L; Kan YW
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):1036-40. PubMed ID: 16407095
[TBL] [Abstract][Full Text] [Related]
9. Stem cell therapy for sickle cell disease: transplantation and gene therapy.
Walters MC
Hematology Am Soc Hematol Educ Program; 2005; ():66-73. PubMed ID: 16304361
[TBL] [Abstract][Full Text] [Related]
10. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
[TBL] [Abstract][Full Text] [Related]
11. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.
Imren S; Fabry ME; Westerman KA; Pawliuk R; Tang P; Rosten PM; Nagel RL; Leboulch P; Eaves CJ; Humphries RK
J Clin Invest; 2004 Oct; 114(7):953-62. PubMed ID: 15467834
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
14. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
15. Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements.
Morgan RA; Unti MJ; Aleshe B; Brown D; Osborne KS; Koziol C; Ayoub PG; Smith OB; O'Brien R; Tam C; Miyahira E; Ruiz M; Quintos JP; Senadheera S; Hollis RP; Kohn DB
Mol Ther; 2020 Jan; 28(1):328-340. PubMed ID: 31628051
[TBL] [Abstract][Full Text] [Related]
16. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for beta-thalassemia.
Malik P; Arumugam PI
Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.
Bank A; Dorazio R; Leboulch P
Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679
[TBL] [Abstract][Full Text] [Related]
19. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
20. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.
Perumbeti A; Higashimoto T; Urbinati F; Franco R; Meiselman HJ; Witte D; Malik P
Blood; 2009 Aug; 114(6):1174-85. PubMed ID: 19474450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
